Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc., 19902 [2021-07718]
Download as PDF
<![CDATA[
19902
Federal Register / Vol. 86, No. 71 / Thursday, April 15, 2021 / Notices
A notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on January 27, 2020 (85 FR 4705).
DEPARTMENT OF JUSTICE
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—PXI Systems Alliance,
Inc.
[FR Doc. 2021–07717 Filed 4–14–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
jbell on DSKJLSW7X2PROD with NOTICES
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Subcutaneous Drug
Development & Delivery Consortium,
Inc.
Notice is hereby given that, on March
31, 2021, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Subcutaneous Drug
Development & Delivery Consortium,
Inc. (‘‘Subcutaneous Drug Development
& Delivery Consortium, Inc.’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
Novartis Pharma AG, Basel,
SWITZERLAND, has been added as a
party to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and Subcutaneous
Drug Development & Delivery
Consortium, Inc. intends to file
additional written notifications
disclosing all changes in membership.
On October 26, 2020, Subcutaneous
Drug Development & Delivery
Consortium, Inc. filed its original
notification pursuant to Section 6(a) of
the Act. The Department of Justice
published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on December 3, 2020 (85 FR 78148).
The last notification was filed with
the Department on January 8, 2021. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on January 28, 2021 (86 FR 7415).
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
[FR Doc. 2021–07718 Filed 4–14–21; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
17:35 Apr 14, 2021
Jkt 253001
Antitrust Division
Notice is hereby given that, on April
2, 2021, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), PXI Systems
Alliance, Inc. (‘‘PXI Systems’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
beltronic Industrie-PC AG, Ru¨dlingen,
SWITZERLAND has been added as a
party to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and PXI Systems
intends to file additional written
notifications disclosing all changes in
membership.
On November 22, 2000, PXI Systems
filed its original notification pursuant to
Section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to Section
6(b) of the Act on March 8, 2001 (66 FR
13971).
The last notification was filed with
the Department on January 18, 2021. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on February 12, 2021 (86 FR 9371).
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
[FR Doc. 2021–07716 Filed 4–14–21; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request;
Excavations (Design of Cave-In
Protection Systems)
Notice of availability; request
for comments.
ACTION:
The Department of Labor
(DOL) is submitting this Occupational
SUMMARY:
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Safety and Health Administration
(OSHA)-sponsored information
collection request (ICR) to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995
(PRA). Public comments on the ICR are
invited.
DATES: The OMB will consider all
written comments that agency receives
on or before May 17, 2021.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Comments are invited on: (1) Whether
the collection of information is
necessary for the proper performance of
the functions of the Department,
including whether the information will
have practical utility; (2) if the
information will be processed and used
in a timely manner; (3) the accuracy of
the agency’s estimates of the burden and
cost of the collection of information,
including the validity of the
methodology and assumptions used; (4)
ways to enhance the quality, utility and
clarity of the information collection; and
(5) ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
automated collection techniques or
other forms of information technology.
FOR FURTHER INFORMATION CONTACT:
Crystal Rennie by telephone at 202–
693–0456, or by email at DOL_PRA_
PUBLIC@dol.gov.
SUPPLEMENTARY INFORMATION: Design of
cave-in protection systems are needed
by employers in the construction
industry and OSHA compliance officers
to ensure that cave-in protection
systems are designed, installed, and
used in a manner to protect workers
adequately. For additional substantive
information about this ICR, see the
related notice published in the Federal
Register on October 21, 2020 (85 FR
67013).
This information collection is subject
to the PRA. A Federal agency generally
cannot conduct or sponsor a collection
of information, and the public is
generally not required to respond to an
information collection, unless the OMB
approves it and displays a currently
valid OMB Control Number. In addition,
notwithstanding any other provisions of
law, no person shall generally be subject
to penalty for failing to comply with a
collection of information that does not
E:\FR\FM\15APN1.SGM
15APN1
]]>Agencies
[Federal Register Volume 86, Number 71 (Thursday, April 15, 2021)]
[Notices]
[Page 19902]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-07718]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Subcutaneous Drug Development & Delivery
Consortium, Inc.
Notice is hereby given that, on March 31, 2021, pursuant to Section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug Development &
Delivery Consortium, Inc. (``Subcutaneous Drug Development & Delivery
Consortium, Inc.'') has filed written notifications simultaneously with
the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Novartis Pharma AG, Basel, SWITZERLAND, has been added as
a party to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and Subcutaneous Drug Development &
Delivery Consortium, Inc. intends to file additional written
notifications disclosing all changes in membership.
On October 26, 2020, Subcutaneous Drug Development & Delivery
Consortium, Inc. filed its original notification pursuant to Section
6(a) of the Act. The Department of Justice published a notice in the
Federal Register pursuant to Section 6(b) of the Act on December 3,
2020 (85 FR 78148).
The last notification was filed with the Department on January 8,
2021. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on January 28, 2021 (86 FR 7415).
Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2021-07718 Filed 4-14-21; 8:45 am]
BILLING CODE P
